Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T21:37:40.266Z.
Consensus retrieved: 2026-10-06T14:02:12.969Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:37:40.266Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f4a2befa970cab8c9956b6d8c2bddfeceb0bcb8bde8cbc5a5c0f5a0c0e258424
Forward PE Ratio (N/A) = Dated Quote Price ($79.57) / Consensus Forward EPS ($-2.90)
FORWARD PE RATIO
N/A
Monopar Therapeutics Inc.
Market Cap
$533.04M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Monopar Therapeutics Inc. (MNPR) | $533.04M | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | N/A |
| Shattuck Labs, Inc. (STTK)vs › | $529.58M | N/A |
| ProKidney Corp. (PROK)vs › | $538.01M | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $524.43M | N/A |
| Altimmune, Inc. (ALT)vs › | $519.25M | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $548.51M | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.32M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $79.57, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.90 | $-5.09 – $-2.02 | 8 | n/m |
| 2027-12-31 | $-2.46 | $-5.21 – $-0.84 | 7 | n/m |
| 2028-12-31 | $-1.86 | $-3.99 – $0.54 | 7 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
